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THE DEVELOPMENT OF INTRATUMORAL HETEROGENEITY IN OVARIAN 
TUMORS: ROLE OF CANCER STEM CELLS IN DISEASE PROGRESSION 
 
 
ELAINE P. LUNSFORD 
 
 
 
ABSTRACT 
 
Like with many cancers, a single ovarian tumor can display remarkable diversity 
in genetics, epigenetics, expression profiles, microenvironment and cell 
differentiation and plasticity. This so-called intratumoral heterogeneity (ITH) is 
thought to greatly increase mortality by enabling tumors to adapt quickly to 
therapy, metastasize, and recur, thus the study of ITH holds great clinical 
significance. Clonal evolution and cancer stem cell (CSC) theory are two models 
for the initiation and propagation of a tumor, which offer differing views on the 
way that ITH is developed and maintained. In the clonal evolution model, cancer 
arises from a single cell and, through genetic instability, proliferates into a diverse 
population of daughter cells, which develop additional mutations and undergo 
Darwinian selection under the influence of the tumor microenvironment. Each cell 
of the clonal evolution model may be capable of initiating a tumor independently. 
In CSC theory, cancer arises from the transformation of a stem cell that has the 
capacity to self-renew and differentiate into a diverse population of daughter 
cells. Each cell is NOT capable of tumorigenesis as most  are terminally 
differentiated and do not harbor self-renewing capabilities. According to CSC 
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theory, small, rare subpopulations of CSCs persist throughout chemotherapy and 
are responsible for repopulating the heterogeneous tumor post-treatment. The 
hypothesis that CSCs may play a role in ovarian cancer progression is the 
subject of this thesis. Many studies have detected the presence of stem cell 
markers and dysregulated stem cell signaling pathways in ovarian cancer, but 
doubts remain as to the existence of ovarian CSCs; critics have pointed out 
inherent flaws in experimental designs meant to identify and characterize CSCs. 
For example, the presence of cancer cells which express the stem cell marker 
CD133 has been correlated to both positive and negative impacts on prognosis. 
Further challenging the study of ovarian CSCs is the lack of consensus on the 
true cell of origin for ovarian cancer – whether it be from the fallopian tube 
epithelium or ovarian surface epithelium, or elsewhere in the peritoneal cavity – 
this will have important implications for the identification and characterization of 
tumorigenic ovarian CSCs. Advocates of clonal evolution theory have put forth 
incredible effort to reveal the extent of inter and intra-tumoral heterogeneity in 
ovarian cancer, and from these data there has arisen a general consensus that 
cancer cell populations do evolve in a step-wise fashion, accumulating additional 
mutations over time. The involvement of cancer stem cells in this progression 
and how exactly they fit in (as a cell of origin or arising from genetic mutations), 
as well as their significance for different cancer types, is a question worth 
answering. Despite the challenges facing the study of ovarian CSCs, the clinical 
impact of cells with stem-like properties has been repeatedly demonstrated, 
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especially with regard to metastatic processes and chemoresistance. Moreover, 
new drugs which target stem cell pathways have proven effective in the 
treatment of ovarian cancer. The existence of a rare subset of cells that have 
enhanced tumor-initiating properties is apparent in ovarian cancer, and more 
work is needed to characterize the unique identifiers and behavior of these cells 
in vivo. Future experiments involving lineage tracing promise to deepen our 
understanding of the nature of ovarian CSCs and address whether normal stem 
cells might serve as the cell of origin.  
viii 
 
TABLE OF CONTENTS 
 
TITLE PAGE …………………………………………………….……………………….i 
COPYRIGHT PAGE…………………………………………………………………….ii 
READER’S APPROVAL PAGE…………………………………………………….…iii 
ACKNOWLEDGEMENTS .................................................................................... iv 
ABSTRACT ...........................................................................................................v 
TABLE OF CONTENTS ..................................................................................... viii 
LIST OF TABLES..................................................................................................x 
LIST OF FIGURES...............................................................................................xi 
ABBREVIATIONS ............................................................................................. xiii 
INTRODUCTION.................................................................................................. 1 
The Importance of Intratumoral Heterogeneity.................................................. 1 
Major Concepts and Discoveries in the Field of Intratumoral Heterogeneity..... 4 
Models for Intratumoral Heterogeneity: Clonal Evolution Theory .................... 11 
Models for Intratumoral Heterogeneity: Cancer Stem Cell Theory .................. 15 
Specific Aims................................................................................................... 19 
INTRATUMORAL HETEROGENEITY IN OVARIAN CANCER.......................... 20 
Ovarian Cancer Subtypes and Pathogenesis.................................................. 20 
Genetic, Epigenetic and Expression Profiles................................................... 29 
Microenvironment............................................................................................ 39 
Differentiation and Cell Plasticity..................................................................... 44 
ix 
 
THE ROLE OF CANCER STEM CELLS IN HETEROGENEOUS OVARIAN 
TUMORS............................................................................................................ 46 
A Review of Stem Cell Biology........................................................................ 46 
Stem Cells and Cancer ................................................................................... 55 
Evidence for Ovarian Cancer Stem Cells ........................................................ 61 
Validity of the cancer stem cell model in predicting intratumoral  
      heterogeneity............................................................................................. 69 
CONCLUSIONS AND FUTURE DIRECTIONS.................................................. 75 
APPENDIX I ....................................................................................................... 78 
APPENDIX II ...................................................................................................... 80 
REFERENCES .................................................................................................. 81 
CURRICULUM VITAE........................................................................................ 98 
 
 
x 
 
LIST OF TABLES  
 
 
Table Title Page  
1 Timeline: Highlights in the Study of Intratumoral 
Heterogeneity 
8 
2 Ovarian Cancer Subtypes 23 
3 Recurrent Genetic Mutations Found in HGSC 31 
4 Regulators of Embryonic Stem Cell Differentiation 80 
5 Qualities of a Cancer Stem Cell 61 
6 Ovarian Cancer Stem Cell Markers 64 
 
xi 
 
LIST OF FIGURES  
 
 
Figure  Title Page  
1 Clonal Evolution Model 13 
2 Phylogenetic Tree of Acute Myeloid Leukemia 14 
3 Cell Division and Partitioning of DNA Strands 16 
4 Cancer Stem Cell vs. Clonal Evolution Model 18 
5 Ovarian Cancer Subtypes 22 
6 Hypothesized Progression from Site of Origin in Serous 
Ovarian Carcinoma 
26 
7 Pathogenesis of Ovarian Cancer Subtypes from 
Hypothesized Sites of Origin 
27 
8 Ras-Raf and PI3K-AKT Signaling Pathways 34 
9 Wnt Signaling Pathway 36 
10 The SWF/SNF complex including BAF250A 37 
11 The Cells of the Heterogeneous Tumor Microenvironment 40 
12 Interaction pathways in the ovarian cancer 
microenvironment 
42 
13 Key steps in tumor metastasis involve EMT and MET 
programs 
45 
14 Regulatory Pathways in Embryonic Stem Cells 47 
xii 
 
15 Hematopoeitic Stem Cells 48 
16 The Notch Pathway 51 
17 Wnt Signaling Pathway 52 
18 The Hedgehog Pathway 53 
19 TGF-beta Superfamily Signaling Pathways 54 
20 Metastatic Teratocarcinoma 56 
21 Normal Stem Cell Vs. Cancer Stem Cell 58 
22 RT-PCR reveals connection between CD24 and stem cell 
function 
67 
 
xiii 
 
ABBREVIATIONS  
 
 
AML   acute myeloid leukaemia  
BMPs   bone morphogenic protein  
BRCA1/2  breast cancer type 1/2 susceptibility gene 
CAF    cancer associated fibroblast 
CAF   cancer associated fibroblasts  
CCC    Clear Cell Carcinoma 
CGL   Chronic Granulocytic Leukemia  
CK1   casein kinase 1  
CoR   corepressor  
CSC   cancer stem cell 
EC    Endometriod Carcinoma 
EGFR   Epidermal growth factor receptor 
EMT   epithelial-mesenchymal transition  
ERK   extracellular signal-regulated kinases  
EZH2   enhancer of zeste homolog 2’  
GSIs   gamma-secretase  Ibnhibitors 
GSK   glycogen synthase kinase 
HGSC   High Grade Serous Carcinoma 
HSCs   hematopoeitic stem cells  
ICN   intracellular fragment of Notch  
xiv 
 
IL   Interleukin 
ITH   Intratumoral heterogeneity  
LGSC   Low Grade Serous Carcinoma 
MAPK   mitogen-activated protein kinase 
MC    Mucinous Carcinoma  
MET   mesenchymal-epithelial transition  
MSCs   Mesenchymal stem cells  
Pi3K   phosphoinositide 3-kinase 
SBT   serous borderline tumor 
SCNAs  somatic copy number alterations 
SMO   receptor Smoothened  
STIC   serous tubal intraepithelial carcinoma 
TAM     tumor associated macrophage 
TAMs   Tumor-associated macrophages  
TGF-β   transforming growth factor beta  
TIC   tubal intraepithelial carcinoma 
 
1 
 
INTRODUCTION 
 
In the first part of this thesis, intratumoral heterogeneity (ITH) in ovarian cancer 
will be explored, including contributions of genetic mutations, epigenetic 
alterations, microenvironment and cell plasticity, and how each of these aspects 
are critical for disease progression. Next, the extent to which ITH in ovarian 
cancer can be explained by certain models of tumor progression, namely clonal 
evolution and cancer stem cell theory, will be assessed using data from the 
literature. In the following introduction, the clinical relevance and history of the 
field of ITH will be detailed, and background on the two models of tumor 
progression, clonal evolution and cancer stem cell theory, will be given.  
The Importance of Intratumoral Heterogeneity  
Ovarian cancer remains a highly lethal disease, with the 5-year survival rate for 
all types being only 44%, and even less for invasive epithelial types diagnosed at 
Stage III or IV (Cancer.org (n.d.)). Unfortunately, because women remain largely 
asymptomatic throughout the early stages of disease, 75% of ovarian cancer is 
diagnosed at stage III and IV (Marcus, Maxwell, Darcy, Hamilton, & McGuire, 
2014). Efforts toward earlier detection have produced mixed results. On one 
hand, studies point out that screening of asymptomatic women has not proven 
beneficial and may lead to unnecessary surgery (Reade, Riva, Busse, Goldsmith, 
& Elit, 2013). Other studies show there is benefit, but limitations in study design 
render the results inconclusive. Current screening studies using new algorithms 
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to assess CA-125 levels are underway, with results expected in 2015 (Menon, 
Griffin, & Gentry-Maharaj, 2014). These new studies show increasing promise 
toward a recommendation for ovarian cancer screening in the general public 
which could possibly lead to earlier detection and decreased mortality. 
 
Once diagnosed, patients typically undergo a debulking surgery along with 
platinum/taxane chemotherapy (Collinson, Seligmann, & Perren, 2012). Despite 
many patients showing initial sensitivity to treatment, the mostly likely outcome is 
recurrence and death (Lopez, Banerjee, & Kaye, 2013; Marcus et al., 2014). 
Thus, as for many cancers, recurrence is a major challenge to the successful 
treatment of ovarian cancer. Although chemotherapy can successfully eliminate a 
large bulk of the tumor, certain cells, particularly at advanced stages of the 
disease, can develop or possess an inherent resistance to treatment (Collinson, 
Seligmann, & Perren, 2012). The fact that certain cells respond differently to 
treatment illustrates a widely-known and important aspect of cancer biology – 
namely that cells within tumors evolve to form a complex mix of subpopulations 
which differ widely in genetic and phenotypic traits. Some of these traits may 
confer survival advantages that are responsible for the persistence of cancerous 
subpopulations during and after treatment. Understanding the nature of these 
advantages, as well as the mechanisms underlying the development of resistant 
subpopulations will help in designing more effective treatment strategies. 
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Intratumoral heterogeneity has also been implicated in metastasis, as well as 
tumor expansion, relapse, and drug resistance (Brabletz, 2012; Elshamy & Duhé, 
2013; Scheel & Weinberg, 2012). Throughout the evolution of a tumor, 
transformations occur such that cells develop certain “hallmarks of cancer,” 
including the ability to self-sustain growth factors, evade suppression of growth, 
escape apoptosis, self-renew, promote and maintain angiogenesis, and finally 
invade other host tissues and metastasize (Hanahan & Weinberg, 2011). At this 
stage, the invasive cells are said to be malignant. Many have proposed that 
these transformed subpopulations evolve in a Darwinian fashion, with cells 
undergoing a selection process whereby an aggressive, dominant population 
emerged (Greaves & Maley, 2012; Murugaesu, Chew, & Swanton, 2013).  
Current theory suggests, however, that subpopulations which are only partially 
transformed may work together, in commensal or mutual relationships. This 
synergy could allow for the hallmarks of cancer to be acquired much earlier, 
before one subpopulation has become fully transformed, so that metastasis 
occurs faster than a Darwinian model would predict (Axelrod, Axelrod, & Pienta, 
2006).  
This theory of cooperation among subpopulations illustrates the importance of 
understanding intratumoral heterogeneity and the ways in which it can aid in 
tumor progression. Additional features of intratumoral heterogeneity, such as 
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contributions from the tumor microenvironment and cell plasticity, play crucial 
roles in the progression of disease and will be discussed in later sections. 
 
In summary, ITH has important clinical implications for the successful treatment 
of cancer, for example, while chemotherapy may be effective against a majority 
of the cancer cells, certain subpopulations can uniquely develop resistance and 
cause relapse. Further, ITH is theorized to expedite tumor progression toward 
aggressive metastases, and this process may involve the cooperation of various 
subpopulations. Understanding the nature of ITH will have major clinical 
implications, including the potential to design new drugs which may prevent 
relapse and metastases.  
Major Concepts and Discoveries in the Field of Intratumoral Heterogeneity 
Although the heterogeneous nature of bulk tumors had been recognized for 
some time, the field of intratumoral heterogeneity gained momentum in the late 
1970s and early 1980s, as researchers considered the important implications for 
treatment and prognosis. Observations of phenotypic diversity were reported in 
various cancers, and included findings such as differences in proliferation rates 
(Rabes, Carl, Meister, & Rattenhuber, 1979), variety of cell surface markers 
(Davis, Zava, Locher, Goldhirsch, & Hartmann, 1984), and protein 
phosphorylation (Chakrabarty, Jan, Miller, & Brattain, 1985). In each case, the 
studies emphasized the significance of the findings for treatment response.  
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The clinical significance of intratumoral heterogeneity is the key behind the 
continued interest among researchers. As early as 1965, it was asserted that 
cancer treatment would not be effective without understanding the diversity found 
within the disease (Foulds, 1965). Toward this end, models of tumorigenesis 
were proposed, including a Darwinian evolutionary model, whereby genetic 
instability leads to accumulation of mutations and divergent clonal populations 
within the same tumor (Nowell, 1976). Others proposed mechanisms in which 
tumorigenesis bore striking similarity to embryonic development, such that a 
small population of initiating cells can give rise to a multitude of different cell 
phenotypes (Nicolson, 1987). Still others emphasized the “societal” aspect of 
tumors whereby various subpopulations work together to influence tumor growth 
and behavior (Heppner, 1993). 
Adding to the recognized importance of the field was the proposal that 
intratumoral heterogeneity promoted metastatic processes (Fidler, 1978) as well 
as drug resistance (Sirachý, 1979). In order to achieve malignancy, it was 
suggested that a tumor would need to diversify its population to manifest key 
alterations in cell physiology, termed ‘the hallmarks of cancer’ (Hanahan & 
Weinberg, 2000). These changes would allow a cancer cell to invade the 
surrounding stroma, enter the blood stream, and seed new tumor sites elsewhere 
in the body.  
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Thus, by the year 2000, the concept that intratumoral heterogeneity is considered 
a necessary component of cancer progression was emerging, and various 
models were being developed to explain the mechanisms behind creating this 
diversity. The key characteristics defining a malignant turning point, the 
‘hallmarks of cancer,’ created a framework within which to study intratumoral 
heterogeneity.  
Other major concepts in the field of intratumoral heterogeneity include the 
contribution of epigenetic alterations – changes that affect gene transcription but 
do not involve alterations to the genome sequence – as an additional source of 
intratumoral heterogeneity (Frost & Kerbel, 1983). In parallel, the extracellular 
environment as well as the inflammatory response were shown to enhance and 
perpetuate intratumoral heterogeneity, cell proliferation, survival and invasion 
(Allavena, Sica, Solinas, Porta, & Mantovani, 2008; Gillies, Schornack, Secomb, 
& Raghunand, 1999; Liotta & Kohn, 2001; Talmadge, 2011). 
In the last 10 years, the debate over which model of tumorigenesis best 
describes the intratumoral heterogeneity found in various cancers has become a 
hot topic in cancer research. The idea of a ‘cancer stem cell’ has gained 
popularity and stands to challenge the existing theory of clonal evolution, as well 
as provide compelling explanations as to the mechanisms behind malignancy 
and drug resistance (Maugeri-Saccà, Vigneri, & De Maria, 2011; O’Brien, Kreso, 
& Jamieson, 2010; Soltysova, Altanerova, & Altaner, 2005; Tu, Lin, & Logothetis, 
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2002). Adding complexity to the cancer stem cell theory has been the most 
recent evidence for the epithelial-mesenchymal transition (EMT) as a necessary 
step for metastasis, and the plasticity of cellular differentiation which challenges 
the traditional hierarchy of ‘one-way’ differentiation originally proposed by the 
stem cell model (Kreso & Dick, 2014; Marjanovic, Weinberg, & Chaffer, 2013; 
Polyak & Weinberg, 2009). Cells which undergo an EMT bare striking 
resemblance to cancer stem cells with regard to cell surface markers and active 
signaling pathways which control cell behavior, and thus the theory of cancer 
stem cells has merged to some degree with the EMT, at least with regards to 
metastatic progression. 
The prevailing theories of tumorigenesis, clonal evolution and cancer stem cell 
theory, will be outlined in the following section. A timeline of the major events and 
influential papers in the study of intratumoral heterogeneity is given in Table 1.  
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Table 1. Timeline: Highlights in the Study of Intratumoral Heterogeneity 
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Table 1 continued. Timeline: Highlights in the Study of Intratumoral Heterogeneity 
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Table 1 continued. Timeline: Highlights in the Study of Intratumoral Heterogeneity 
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Table 1 continued. Timeline: Highlights in the Study of Intratumoral Heterogeneity 
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Models for Intratumoral Heterogeneity: Clonal Evolution Theory 
During the time that cancer was being redefined as a complex disease of multiple 
cell types, differing in surface protein expression, DNA ploidy, and genetic 
makeup, the question of how this progression occurs became of increasing 
interest.  An early yet persistent theoretical model for the evolution of a tumor 
(Nowell, 1976) built upon the widely held notion that most neoplasms originated 
from a single cell or ‘stem line’, and emphasized the role of genetic instability and 
selection advantages throughout the evolution of ‘clones’ (daughter cells of the 
original neoplastic cell), suggesting a Darwinian progression (Figure 1). The 
effect of local tissue environment and drug treatment on tumor evolution, with 
particular reference toward fostering selection of subclones which persist in 
metastatic sites in contrast to the primary tumor, is also emphasized. Evidence 
for this model is supported by cytogenetic data, however at the time, limitations 
are noted in as much as genetic mapping was unavailable. 
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Figure 1. Clonal Evolution Model. Tumors evolve from a single normal cell 
(indicated by ‘N’) which undergoes a transformation that allows it to escape 
normal cell growth regulation. It rapidly divides, generating clones with increasing 
genetic instability and mutations. Here, Chronic Granulocytic Leukemia (CGL) is 
used as an example. Subpopulations which do not survive are indicated by the 
shaded circles, while those that acquire an additional mutation which confers a 
survival advantage are indicated by the numbers T1 through T6. Significant 
biological events and ploidy number are also indicated throughout the 
progression. Figure taken from (Nowell, 1976). 
 
Today, clonal evolution theory is generally accepted, and advanced versions of 
Nowell’s depiction of CGL progression are plotted in so-called phylogenetic trees 
(Figure 2), which contain step-wise progressive genetic mutations that lead to 
the eventual accumulation of a wide variety of subpopulations both within a 
single tumor and between patients with the same disease (Shlush et al., 2012). 
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Importantly, in the clonal evolution model, every cancer cell is capable of 
generating a tumor, regardless of its position in the evolutionary timeline. 
 
Figure 2.  Phylogenetic Tree of Acute Myeloid Leukemia. Cells were sampled 
from two patients before and after treatment, and genetic sequencing revealed 
mutation progression. With each split in the tree, a new genetic identifier is found 
in a population of cells. The distance between each split in the tree indicates “cell 
depth,” and is related to the number of replications the cells underwent before 
gaining a unique genetic identity from the root. Large depths indicate frequent 
replication, while shallow depths indicate rare replication of a subclone. Figure 
taken from (Shlush et al., 2012). 
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The Swanton group has published extensively on the importance of genomic 
instability for generating intratumoral heterogeneity, including the selection of the 
‘fittest’ clones within a  given microenvironment or therapeutic context (Burrell, 
McGranahan, Bartek, & Swanton, 2013). This mechanism has essentially been 
proven as an influential force in tumorigenesis, and all other models have 
incorporated clonal evolution as part of the process alongside new theories of 
cancer development. Controversy has ensued, however, about the extent to 
which clonal evolution theory is responsible for intratumoral heterogeneity. 
Models for Intratumoral Heterogeneity: Cancer Stem Cell Theory 
A stem cell is an unspecialized progenitor which can give rise to a variety of more 
specialized cells, and is capable of self-renewal. In adults, stem cells make up 
rare populations that remain relatively dormant in tissues, waiting for queues 
from the extracellular environment to divide and differentiate. Around the same 
time that clonal evolution theory began to unfold, investigators were examining 
stem cells and how mutations in an immortal cell line may be involved in the 
development of a tumor. 
A model was proposed by John Cairns in 1975 in which “immortal” strands of 
DNA were passed on from one stem cell to its daughter stem cell, while its other 
daughter cell received a “mortal” strand and went on to terminally differentiate 
(Figure 3). In this way, genetic mutations could be immortalized and, as they 
accumulate throughout a person’s lifetime, dramatically increase the risk of 
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developing cancer, since several mutations are required for cancer to occur 
(Cairns, 1975; Knudson, Strong, & Anderson, 1973). One can imagine the 
accumulation of mutations would be many fold higher if a stem cell were to divide 
into two daughter stem cells, a process called ‘symmetric division’ for example 
(Kondo, 1977), creating two immortal DNA strands bearing oncogenic mutations 
instead of one. 
 
Figure 3. Cell Division and Partitioning of DNA Strands.  a) normal semi-
conservative cell division where each parental DNA strand is randomly assigned 
to a daughter cell. A mutation is indicated by the double strike. b) stem-cell 
division where one parental strand (solid line) is preferentially passed on to stem 
cell progeny, in effect this “older” strand becomes immortalized. The other 
“younger” strand (dashed line) is passed on to daughter cells which go on to 
terminally differentiate. A mutation is indicated by the double strike. Taken from 
(Cairns, 1975). 
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Today, stem cell theory has taken hold and is a hot topic in the scientific 
community, although some would argue, little is understood about stem cell 
differentiation, including Cairns’ model of the immortalized DNA strand (Sell, 
2004). In brief, cancer stem cell theory proposes that tumors are initiated when a 
normal stem cell undergoes a transformation which leads to dysregulation of its 
regulatory mechanisms. As a result, the stem cell divides abnormally, giving rise 
to either more stem cells, differentiated daughter cells, or both, and creating a 
diverse tumor environment of various phenotypes. Alternatively, differentiated 
cells which have adopted a mutator phenotype can de-differentiate and attain 
stem-like characteristics, which impart the capacity for self-renewal and thus 
tumorigenesis at metastatic sites as well (Figure 4A). At the heart of the cancer 
stem cell model is the hierarchy, whereby the tumorigenic stem cell is at the 
apex, and is capable of self-renewal and capacity to regenerate all phenotypic 
diversity found in a tumor (O’Brien et al., 2010). 
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Figure 4. Cancer Stem Cell vs. Clonal Evolution Model. Two approaches for 
tumorigenesis. A) Classical stem cell theory whereby normal stem cells capable 
of self-renewal undergo a transformative genetic mutation, creating a cancer 
stem cell, which can differentiate to generate all other cells that comprise a 
tumor. B) Clonal evolution model whereby any cell can initiate a tumor, and 
through genetic mutations, establish intratumoral heterogeneity. These cells may 
also possess self-renewing capacity which was obtained through stochastic 
processes. Lightening bolts represent mutagenesis and asterisks represent 
mutations. Taken from (Campbell & Polyak, 2007). 
 
 
In the following thesis, intratumoral heterogeneity within the context of ovarian 
cancer will be explored, as well as the applicability of the cancer stem cell model 
in describing this heterogeneity. 
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Specific Aims 
 
Specific aims of the following thesis include: 
1. Comprehensive review of literature to characterize the nature and 
extent of intratumoral heterogeneity found in ovarian cancer. 
2. Investigation into the current evidence for the ovarian cancer stem 
cells.  
3. Conclusion on the validity of the cancer stem cell model in predicting 
intratumoral heterogeneity in ovarian cancer. 
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INTRATUMORAL HETEROGENEITY IN OVARIAN CANCER 
 
Ovarian cancer is not a single disease, but includes several subtypes which 
range from relatively benign to aggressive, metastatic tumors. These subtypes 
vary greatly in morphology, genetic alterations, and interestingly, the proposed 
cell of origin, which in most cases is theorized to be from tissues outside of the 
ovary. In the following section will outline the ovarian cancer subtypes and 
discuss their proposed pathogenesis. Next, we will focus on intratumoral 
heterogeneity within ovarian cancer, specifically, how the genetic and epigenetic 
alterations, microenvironment, and cell plasticity contribute to the remarkable 
diversity of cancer cell populations typically found in this disease. 
 
Ovarian Cancer Subtypes and Pathogenesis 
Ovarian cancer is not a single disease, but a grouping of cancers which have 
differing behaviors and morphologies, cells of origin and responses to treatment. 
Beyond the histological appearance of the cells (Figure 5), each subtype differs 
in its clinical course and genetic expression profile, although much overlap has 
been known to occur. The characteristics of each subtype of ovarian cancer are 
summarized in Table 2.  
The five most common forms of ovarian cancer are very diverse, yet high grade 
serous carcinoma research dominates the literature, presumably due to its 
aggressive nature and high frequency. An attempt was made to reclassify 
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ovarian cancer into only two types, ‘Type I and Type II’ (Kurman & Shih, 2010), 
however this approach has been criticized for lumping together the more rare 
subtypes of ovarian cancer and thus hindering our understanding and progress 
toward managing these important diseases (McCluggage, 2011; Prat, 2012). 
Although rare, the clear cell carcinoma subtype is actually more deadly when 
diagnosed in the late stages than the common HGSC, because of its poor 
response to chemotherapy (Prat, 2012). The study of this particular subtype of 
cancer is made difficult by its rarity, however recognition of it as a distinct form 
has advantages for a much needed focused study.  
For a detailed outline of each subtype see Appendix I.  
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Figure 5. Ovarian Cancer Subtypes. A) High-Grade Serous Carcinoma 
(HGSC); B) Low-Grade Serous Carcinoma (LGSC); C) Mucinous Carcinoma 
(MC); D) Endometriod Carcinoma (EC); E) Clear Cell Carcinoma (CCC) 
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Table 2. Ovarian Cancer Subtypes. Summary of distinguishing features of five 
ovarian cancer subtypes, which account for nearly 98% of all ovarian cancer 
manifestations. HGSC – High Grade Serous Carcinoma; LGSC – Low Grade Serous 
Carcinoma; MC – Mucinous Carcinoma; EC – Endometriod Carcinoma; CCC – Clear Cell 
Carcinoma. 
 
The pathogenesis of ovarian cancer including the cell of origin is not yet 
understood and is believed by some to be the missing piece of a puzzle that 
would allow for early detection and effective treatment ( Kurman & Shih, 2010; 
Prat, 2012). Determining the cell of origin requires identification of a precursor 
condition, before the tumor overruns the tissue and obscures the initiation site. 
 HGSC LGSC MC EC CCC 
Frequency 68-71% <5% 3-4% 10% 10% 
Phenotype Aggressive Mostly benign Mostly 
benign 
Very benign Benign if 
detected 
early, 
aggressive if 
late stage 
Common 
genetic 
signature 
and 
expression 
profile 
TP53, 
BRCA, 
WT1, p16, 
ER, Ki67 
Similar 
expression 
profile to HGSC, 
except low Ki67. 
May contain 
BRAF and 
KRAS 
mutations. 
CDX2, 
KRAS, 
CK7 
HNPCC, 
PTEN, 
ARID1A, 
CTNNB1, 
ER 
HNF1-beta, 
ARID1A, 
ARHGDIG 
Cell of 
origin 
Fallopian 
tube or 
ovarian 
surface 
epithelium 
Unknown Unknown Endometriu
m or 
myometriu
m 
Endometrium 
or 
myometrium 
Response 
to therapy 
Initially 
sensitive to 
chemothera
py but 
develops 
resistance 
and recurs 
Unknown, 
preliminary data 
suggests 
insensitivity 
Unknown Sensitive to 
chemothera
py 
Typically 
unresponsive 
to treatment 
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Tubal intraepithelial carcinoma, endometriosis, cysts or borderline tumors 
(Figure 6) have been postulated as precursor lesions to development of cancer. 
Often in ovarian cancer, the disease has advanced well beyond this stage at the 
time of presentation, making it difficult to determine where the abnormality 
started. 
The first study that was able to identify consistent precursor lesions in the 
fallopian tube came out of careful examination of specimens obtained from 
prophylactic salpingo-oophorectomies in women who were positive for BRCA. 
This provided evidence for HGSC cell of origin in the fimbrae for patients with 
hereditary BRCA mutations (Kindelberger et al., 2007). Evidence continues to 
mount in support of the notion that the precursor lesion for ovarian cancer is 
serous tubal intraepithelial carcinoma, (serous TIC or STIC) occurring in the 
distal fallopian tube, however, ovarian surface epithelium cannot be ruled out 
entirely as a potential site of origin (Bowtell, 2010; Kurman, 2013), and it seems 
likely that both regions may be involved in a case-by-case manner. Illustrations of 
the various pathways hypothesized in the early development of ovarian cancer 
subtypes are presented in an influential paper by Kurman & Shih in 2010 (Figure 
7). Non-serous subtypes of ovarian cancer, such as endometriod and clear cell 
carcinoma, are also postulated to originate from tissues outside of the ovary, 
most likely the endometrium. Mucinous carcinoma of the ovary has been 
postulated to originate in the endocervix and other areas, but compelling 
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evidence is lacking for this subtype as well. (Dubeau & Drapkin, 2013). Research 
on these subtypes is limited by the relative rarity of the disease. 
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Figure 7. Pathogenesis of Ovarian Cancer Subtypes from Hypothesized 
Sites of Origin. A) Cells shed from fallopian tube fimbrae generate inclusion 
cysts on the ovary, which can progress to high or low-grade serous carcinoma 
with mutations in TP53 or KRAS/BRAF respectively. Low grade serous 
carcinoma is often preceded by serous borderline tumor (SBT). HGSC can also 
develop from STIC shed from the fimbrae. Occasionally, HGSC can develop from 
LGSC. B) Both endometroid and clear cell carcinoma of the ovary develop from 
retrograde menstruation as a result of endometriosis. Borderline tumors develop 
as an intermediate step in this process. Adapted from (Kurman & Shih, 2010). 
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Despite numerous studies to determine the true origins of ovarian cancer, there 
remains conflicting evidence and many unanswered questions. It should not be 
overlooked that some ovarian tumors present as heterogeneous mixtures of 
various histological phenotypes, and currently there is no evidence that might 
explain this pathogenesis. Furthermore, although the genetic signatures of these 
various subtypes have been more or less defined, it’s crucial to keep in mind the 
fact that these signatures are not all inclusive – and there is much variability 
within subtypes, and overlap between them. For example, high grade serous 
carcinoma subtypes have been characterized as different from other types of 
ovarian cancer for the absence of PI3K pathway involvement, but more recent 
data suggests this pathway is more closely linked to HGSC than previously 
thought (Prat, 2012). The same pathway has been suggested as a characteristic 
of endometriod carcinoma, yet PTEN mutations have been shown to occur in 
only 20% of cases (Prat, 2012). Thus, the variability within subtypes and the 
overlapping nature of their genetic signatures is apparent, and begs the question 
of whether our classification system is misleading research efforts and 
misinforming treatment strategies.  
The possibility that all ovarian cancer subtypes might  share the same cell of 
origin has been suggested in support of the cancer stem cell theory (Shah & 
Landen, 2014). Considering the fact that ovarian cancer can present as 
heterogeneous mixtures of the various subtypes, and the overlapping nature of 
their genetic signatures, further work is warranted to explore this idea. In the next 
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section, a detailed review of the heterogeneity existing in ovarian cancer genetics 
and epigenetics will be given. Until a consensus is reached on the true cell(s) of 
origin, however, our understanding of how intratumoral heterogeneity arises will 
remain incomplete, as will our ability to effectively treat this disease. 
Genetic, Epigenetic and Expression Profiles 
There are a variety of ways in which a cancer genome can be altered, leading to 
changes in protein function or expression levels. Somatic mutations include 
changes in DNA sequence such as point mutations, where one base substitutes 
for another; insertions or deletions of parts of the genome; rearrangements within 
the genome; and amplification, whereby a normal diploid gene which normally 
has only two copies can have up to several hundred copies (also termed ‘somatic 
copy number alterations’ or SCNA). Germline mutations, such as BRCA1/2, are 
associated with increased risk for certain cancers such as ovarian and breast, 
and are not the result of random mutations, but represent permanent, hereditary 
alterations in the genome. In cancer, somatic and germline alterations affect the 
ability of a cancer cell to grow and divide independent of growth factors and other 
regulatory signaling thus obtaining one of the most important hallmarks of 
cancer: chronic proliferation (Hanahan & Weinberg, 2011). 
In addition to genetic mutations, the impact of epigenetic alterations – 
modifications to the genome that affect transcription but do not involve sequence 
alteration – is emerging as a crucial component of tumor progression and 
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heterogeneity. Prominently studied epigenetic factors include hyper/hypo-
methylation of gene promoters and histone acetylation and methylation, both of 
which affect DNA architecture resulting in increases or decreases in gene 
transcription. Hypermethylation of the BRCA1 promoter, for example, was 
discovered in a significant portion of sporadic breast and ovarian tumors, 
indicating the role of the BRCA1/2 gene beyond traditional hereditary mutations 
(Esteller et al., 2000). 
 
Of course as a consequence of genetic and epigenetic alterations, mRNA and, of 
growing importance, microRNA (Voorhoeve, 2010) expression are often found to 
be abnormal in cancer cells. Analyses of expression profiles may provide 
additional insight beyond transcriptional processes.  
Attempts to define and characterize the genetic, epigenetic and expression 
landscape of ovarian cancer have revealed insights into the nature of 
heterogeneity in ovarian cancer. The largest study to date involved a massive 
collaboration by the Cancer Genome Atlas Research Network, a branch of the 
National Institutes of Health, to sequence the coding exons of the genome 
(exome) of 316 patient samples of serous ovarian cystadenocarcinoma, as well 
as analysis of mRNA and microRNA expression, promoter methylation and DNA 
copy number in 489 samples (Cancer Genome Atlas Research Network, 2011). 
Although this study was restricted to high grade serous carcinoma (HGSC), it 
provided strong support for the role of the TP53 oncogene in this subtype, as 
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previously reported (Ahmed et al., 2010). From these data, it appears that 
mutations in TP53 are present in 96-100% of HGSC, and represents the only 
universally shared genetic alteration of any ovarian cancer subtype. Another 
significant finding of the Cancer Genome Atlas and Research Network was the 
alterations in BRCA1/2 gene present in 33% of HGSC cases (including germline, 
somatic and epigenetic silencing). The number of recurrent genetic mutations 
found by this study was low, including only nine identified genes (Table 3); other 
analyses identified 122 missense mutations which were potentially oncogenic but 
not necessarily recurrent, indicating the considerable heterogeneity of genetic 
mutations in HGSC.  
 
 
Table 3. Recurrent Genetic Mutations Found in HGSC. Taken from (Cancer 
Genome Atlas Research Network, 2011). 
 
Copy number analysis, in contrast to genetic mutations, revealed a large number 
of somatic copy number alterations (SCNAs), many of which were recurrent in 
20-50% of tumors (Cancer Genome Atlas Research Network, 2011). Notable 
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examples of SCNAs found were focal amplifications in CCNE1, MYC and 
MECOM, and focal deletions in PTEN, RB1 and NF1. These genes are 
implicated in various signaling pathways, notably RB signaling, PI3K 
(phosphoinositide 3-kinase)-Ras, (mitogen-activated protein kinase- extracellular 
signal-regulated kinases (MAPK-ERK) and transforming growth factor beta (TGF-
β), all of which control some aspect of cell cycle progression, proliferation and 
survival. These data show that there are more commonalities within SNCAs 
among HGSC tumors, and therefore represent a less heterogenous factor in this 
disease than genetic mutations. It was postulated in the report that perhaps the 
prevalence of mutations in DNA repair genes contributed to the high number of 
SCNAs.  
Based on the combined analyses of genetic mutations, copy number variation 
and epigenetic changes, the Cancer Genome Atlas Research Network identified 
four important signaling pathways in HGSC: RB1, PI3K/RAS, NOTCH and 
FOXM1, with FOXM1 being altered in a significant majority of cases (87%), 
followed by RB1 (67%); and PI3K/RAS (45%) and NOTCH (22%) being less 
representative (Cancer Genome Atlas Research Network, 2011). Thus although 
there is remarkable intertumoral heterogeneity of alterations in the various factors 
involved in these pathways, there is less heterogeneity in which pathways are 
involved in HGSC. From the perspective of drug treatment, knowing which 
pathways to target in order to have a large impact on the majority of HGSC cases 
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will have important implications, even if the factors that cause the deregulation 
vary widely. 
 
In contrast to HGSC, low grade serous carcinoma (LGSC) does not involve p53 
mutations and instead is associated with mutations in either KRAS or BRAF (Ho, 
Kurman, Dehari, Wang, & Shih, 2004; Singer et al., 2003). The difference in 
signaling pathway involvement has been suggested to indicate that these two 
forms of serous carcinoma evolve by separate mechanisms, and that LGSC is 
not an “intermediate step” toward development of HGSC (Russell & McCluggage, 
2004). A comparison of the pathways involving p53, KRAS and BRAF are 
illustrated in Figure 8. Of note, there appears to be significant opportunity for 
cross-talk between these two pathways. 
Akt plays a central role in the PI3K pathway and cross-talks with other important 
pathways in cancer biology. In addition to HGSC, clear cell carcinoma has also 
been shown to exhibit activating mutations in the PI3K pathway, specifically 
mutations in the PI3KCA gene itself, which resulted in intense phosphorylated 
Akt activity (Kuo et al., 2009). Mucinous carcinoma exhibits relatively frequent 
mutations in the KRAS gene, similar to LGSC (Naik, Seligmann, & Perren, 2012; 
Xiong et al., 2013).  
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Figure 8. Ras-Raf and PI3K-AKT Signaling Pathways. Dimerization of 
receptor tyrosine kinase EGFR (Epidermal growth factor receptor) occurs upon 
ligand binding of TGF-α or EGF. Subsequent recruitment of Grb2 and other 
signaling molecules result in a cascade of events which lead to cell proliferation, 
growth, and anti-apoptotic effects. Mutations found in ovarian cancer include 
decrease or loss of p53, PTEN and CTNNB1, and increased levels of Ras, Raf, 
PI3K, Akt and RB1. Figure taken from (Jingxian Zhang et al., 2012). 
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Endometrioid carcinoma is the only ovarian cancer subtype to show a relatively 
high frequency of mutation in the CTNNB1 gene, which encodes a protein beta-
catenin that is involved in the regulation of cell growth, proliferation and 
apoptosis, as well as the epithelial to mesenchymal transition (EMT) (Arend, 
Londoño-Joshi, Straughn, & Buchsbaum, 2013; Lech et al., 2013). Beta-catenin 
is a key component of the Wnt signaling pathway (Figure 9), and when sufficient 
unphosphorylated amounts accumulate in the cell cytoplasm, this protein 
migrates to the nucleus to affect gene transcription. Phosphorylation of beta-
catenin by casein kinase 1 (CK1) and GSKb (glycogen synthase kinase) results 
in its ubiquitination and proteosomal degradation.  
Although the CTNNB1 mutation is not typically found in the other subtypes, other 
alterations can similarly lead to the dysregulation of the Wnt pathway and are 
thought to contribute to pathogenesis in these subtypes (Arend et al., 2013). 
Recall from Figure 8 that the PI3K/Akt/mTOR pathway crosstalks with the 
CTNNB1 pathway through inhibition of GSK3b, thus offering an opportunity for 
crosstalk and indirect activation of the Wnt pathway.  
In addition to cell proliferation, survival and migration, the Wnt pathway is an 
important control mechanism in stem cell self-renewal (Pardal, Clarke, & 
Morrison, 2003). This connection will be explored in more detail in a later section 
of this thesis. 
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Figure 9. Wnt Signaling Pathway. A) WNT ligands are not bound to the 
receptor Frizzled, beta-catenin is phosphorylated and degraded, ensuring 
repression of gene transcription by co-repressor groucho. B) WNT ligand binds 
the Frizzled and LRP5/6 receptor complex, preventing phosphorylation of b-
catenin by GSK3b and CK1. B-catenin accumulates in cell cytoplasm and moves 
to nucleus, where it displaces groucho and forms a transcriptional complex with 
TCF/LEF family proteins, BCL9/LGS, and Pygo, and promotes transcription of 
genes involved in cell proliferation and survival. Figure taken from (Arend et al., 
2013). 
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Endometriod and clear cell carcinoma (EC and CCC, respectively), do not show 
alterations in p53, KRAS or BRCA, however have recently been shown to harbor 
frequent mutations in gene ARID1A, with the mutation occurring in 46-57% of 
clear cell carcinoma and 30% of endometriod carcinoma (Jones et al., 2010; 
Wiegand et al., 2010; Wu, Wang, & Shih, 2014). ARID1A codes for a protein, 
BAF250A, which is a critical component of the ATP-dependent chromatin 
remodeling complex, SWI/SNF (see Figure 10). The SWI/SNF complex 
regulates chromatin remodeling and gene transcription, specifically of genes 
involved in repressing the cell cycle, and inhibiting stem cell self-renewal, thus 
loss of this protein would result in increased proliferation and maintenance of the 
stem cell state (Reisman, Glaros, & Thompson, 2009). 
 
Figure 10. The SWF/SNF complex including BAF250A. This complex uses the 
energy of ATP to rearrange nucleosomes and alter the accessibility of DNA for 
transcription and other processes. Mutations in ARID1A are found frequently in 
endometriod and clear cell carcinoma, and result in loss of BAF250A protein 
necessary to form these complexes. The SWF/SNF complex shown is involved in 
cell proliferation and differentiation. Illustration taken from (L. Ho & Crabtree, 
2010). 
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The role of ARID1A is still being explored, and mounting evidence suggests it 
extends far beyond direct regulation of gene transcription, but also is involved in 
DNA repair mechanisms, exhibits co-dependency with p53, and collaborates with 
dysregulation of the PI3K/Akt signaling pathway in tumorigenesis (Wu et al., 
2014). Thus, although these subtypes of cancer do not share the BRCA or p53 
mutations common in high grade serous carcinoma, some similarities in 
dysregulation of DNA repair and apoptosis are observed through the mutation of 
ARID1A and loss of BAF250A.  
In examining the genetic mutations involved in the various subtypes of ovarian 
cancer, the list is actually quite short, involving common oncogenes and tumor 
suppressors – p53, KRAS, RAF, PTEN, BRCA – as well as less common 
mutations in CTNNB1 and ARID1A. Of greater significance within individual 
subtypes seems to be the alterations in cell signaling pathways which do not 
involve mutations but rather somatic copy number alterations and epigenetic 
changes. These alterations confer remarkable intertumoral heterogeneity in 
molecular profiles within various subtypes of ovarian cancer. Despite this 
heterogeneity, however, the signaling pathways affected by it also comprise a 
short list – with the Ras/raf/mek and PI3K/Akt/MAPK dominating current 
research, but emerging roles for the Wnt pathway and others are also on the 
horizon. Cross-talk between these various pathways is an intriguing question 
which deserves further investigation, so as to draw connections and possible 
insight into the pathogenesis of distinct ovarian cancer subtypes, and to predict 
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potential routes of resistance to molecular targeted therapies in order to design 
more effective drugs.  
Microenvironment 
The importance of the microenvironment in tumor progression is gaining 
increasing recognition for virtually all cancer types (Kalluri & Zeisberg, 2006; 
Liotta & Kohn, 2001; Tlsty & Coussens, 2006). The tumor microenvironment is a 
heterogeneous mixture of stromal cells that co-evolve with the cancer itself, 
becoming transformed to support tumor growth (Figure 11) (Briest et al., 2012). 
Specifically, endothelial cells, macrophages and fibroblasts have been shown to 
play a critical role in tumor pathogenesis by inducing angiogenesis and 
remodeling the extracellular matrix, as well as by secreting key cytokines that aid 
in tumor metastasis. The tumor stroma has also been implicated in drug 
resistance (Junttila & de Sauvage, 2013) 
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Figure 11. The cells of the heterogeneous tumor microenvironment. Taken 
from (Junttila & de Sauvage, 2013) 
 
 
Ovarian cancer cells have been shown to signal stromal cells for inducing 
angiogenesis as well as the inflammatory response, both of which aid in cancer 
progression (Gavalas et al., 2013; Shan & Liu, 2009). Ovarian cancer is unique 
among other cancers for its tumor microenvironment, the intraperitoneal space, 
which contains a multitude of organs covered in mesothelium, as well as the fatty 
omentum, and in addition, permits cancer cells to exist suspended in fluidic 
ascites in late stage disease (Naora, 2014). Tumor-stromal interactions are 
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mediated by a variety of cell surface molecules and cytokine signaling (Figure 
12); for example mesothelial attachment is known to be mediated in part by 
CA125-mesothelin, CD44HA, and various integrins (Naora, 2014). Attempts to 
target these molecules and hinder tumor attachment of ovarian cells to the 
mesothelium have largely failed due to the heterogeneous expression of 
particular molecules within the same disease (Cannistra et al., 1993; Heyman et 
al., 2008). 
Angiogenesis is initiated and controlled through cytokine signaling of the ovarian 
cancer cell itself as well as activated stromal cells, which secrete various factors 
including VEGF, FGF-2, IL-6, IL-8, angiopoietin, and PDGF (Martin & Schilder, 
2007).  
Adipocytes are important sources of nutrients and promote proliferation of 
ovarian cancer cells through direct transfer of lipids to the cells (Nieman et al., 
2011). 
A matter of intense research is that ovarian cancer cells induce transformations 
that result in generation of cancer associated fibroblasts (CAFs), which have 
numerous functions to enhance tumor progression (Kalluri & Zeisberg, 2006). 
CAFs arise from a variety of sources, including resident fibroblasts and 
mesenchymal stem cells which  have been recruited from bone marrow or 
adipose tissue (Y. Zhang et al., 2011).  
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Figure 12. Interaction pathways in the ovarian cancer microenvironment. 
Ovarian cancer cells suspended in the peritoneal cavity interact and attach to 
mesothelium, and receive proliferative support from adipocytes. Ovarian cell 
signaling recruits macrophage and fibroblast progenitors to the site of 
implantation, and induces their transformation into “cancer associated” support 
cells. Influence on immune cell reactivity is also mediated by tumor cell signaling 
as well as cancer associated stromal cells. TAM – tumor associated 
macrophage; CAF – cancer associated fibroblast. Taken from (Naora, 2014). 
 
 
 
Transformation of cells into CAFs is mediated by TGF-β signaling from the 
ovarian cancer cells (Ko et al., 2012), and are important for tumor growth and 
proliferation, as well as metastasis. They have been further implicated in tumor 
initiation, although the exact mechanisms of these processes are not yet 
understood (Kalluri & Zeisberg, 2006).  
Tumor-associated macrophages (TAMs) are abundant in ovarian cancer ascites 
are known to promote tumor progression by inhibiting the adaptive immune 
system through expression of immunosuppressive cytokines such as interleukin 
(IL)-10, TGF-β, CCL17, CCL18, and CCL22 (Naora, 2014; Yigit, Massuger, 
Figdor, & Torensma, 2010). In addition, TAMs are known to promote tumor 
invasion and metastasis (Quail & Joyce, 2013), and specific studies have 
confirmed this link in ovarian cancer mouse models (Neyen et al., 2013). 
In summary, the tumor microenvironment is both remarkably heterogeneous and 
functionally influential aspect of cancer biology, and is closely associated with 
tumor initiation, progression and metastasis. The intimate cross-talk between the 
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tumor and stromal cells is a large area of research that promises new avenues 
for targeted therapy. 
Differentiation and Cell Plasticity 
Of recently intensified interest in the study of intratumoral heterogeneity is the 
ability of cancer cells to undergo epigenetic changes which influence the degree 
to which they display an epithelial or mesenchymal phenotype. The epithelial-
mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) are 
programs thought to underlie the ability of cancer cells to develop all the 
necessary ‘hallmarks’ required for metastasis: whereby certain cancer cells 
escape the confines of the tumor, enter the vasculature and travel to distant sites 
where they then exit the vasculature and set up new colonies (Figure 13).  
Until recently, while it was recognized that metastasis is associated with loss of 
cell adhesion molecules such as E-cadherin, N-cadherin and shifts in integrin 
expression,  the mechanism was poorly understood (Hanahan & Weinberg, 
2000). Current research has implicated EMT as the driver behind metastasis, 
certain transcription factors, named Snail, Slug, Twist, and Zeb1/2, have been 
shown to repress the epithelial phenotype when activated and thus play a critical 
role in cell plasticity. Beyond EMT, less is known about the reverse process, 
which involves extravasation and seeding in a new microenvironment, apparently 
involving MET. Research has been directed toward cancer stem cells as playing 
a role in this process, especially in light of their tumorigenic properties (Scheel & 
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Weinberg, 2012). Connections between cancer stem cells, the EMT/MET 
programs and metastasis will be revisited in a later section of this thesis.  
 
 
 
Figure 13. Key steps in tumor metastasis involve EMT and MET programs. 
A select subpopulation of cancer cells obtain a mesenchymal phenotype which 
allows them to migrate away from the primary tumor, intravasate, circulate to 
distant sites, extravasate, and undergo MET to generate a new colony with the 
differentiated epithelial phenotype of the original tumor. Taken from (Scheel & 
Weinberg, 2012) 
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THE ROLE OF CANCER STEM CELLS IN HETEROGENEOUS OVARIAN 
TUMORS 
A Review of Stem Cell Biology 
A stem cell is a multi, pluri, or toti-potent cell capable of differentiating into 
various more specialized cells. Totipotent stem cells have the greatest plasticity, 
or ability to differentiate into the most versatile progeny, while the multipotent 
stem cell has the least plasticity, or limited paths of differentiation (Yamanaka & 
Ralston, 2010).  Totipotent stem cells are only found during embryogenesis. In 
addition to producing differentiated progeny, stem cells are capable of self-
renewal, and their actions are very carefully regulated through cell-cell and cell-
matrix interactions, as well as through various signaling molecules.  
During embryogenesis, stem cells generate all tissues of the body. Determination 
of cell fate involves specific genes and transcription factors, however, other 
mechanisms that involve position, polarization, shape, signaling and division 
plane probably play a greater role in the earlier stages of lineage specification 
(Yamanaka & Ralston, 2010). By extension, in order for cell position to play a 
role in fate, cells must have a sense of polarity and spatial awareness brought 
about by cell-cell contacts.  
Differential expression of transcription factors leads to further specialization into 
inner cell mass (future fetus and yolk sac) and trophoblast layer (placental tissue) 
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during embryogenesis. These factors and their roles are summarized in Table 4 
(Appendix II). 
At the heart of embryonic stem cell regulation are the transcription factors Oct4, 
Sox2 and Nanog, which are responsible for maintaining pluripotency and self-
renewal capabilities. Their activation is mediated through various signaling 
pathways, as shown in Figure 14.  
 
 
Figure 14. Regulatory Pathways in Embryonic Stem Cells. Both LIF-Stat and 
BMP pathways are essential to embryonic stem cell self-renewal in the mouse, 
but LIF-JAK-STAT is dispensable in human. JAK-STAT pathway activates KLF4 
(not shown) which activates Sox2. FGF-MEK pathway (not shown) initiates 
differentiation. PI3-kinase (not shown) activates Tcf3 through LIF. Activin/Nodal 
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/TGFb and FGF are required for human embryonic stem cells. Wnt pathway 
signaling is required for both mouse and human embryonic stem cell self-
renewal. Figure taken from (Heng & Ng, 2010). 
 
Various tissue-specific adult stem cells (referred to from here as ‘stem cells’) 
have been identified. Perhaps the most extensively studied are hematopoeitic 
stem cells (HSCs), which reside in bone marrow and can differentiate into any of 
the various blood cells (Figure 15). HSCs follow a strict hierarchy where each 
division gives rise to a more differentiated cell, one that is committed to a 
particular phenotype. 
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Figure 15. Hematopoeitic Stem Cells. Multipotent stem cells can self-renew 
and give rise to multipotent progenitors. These progenitors will then differentiate 
and commit to a particular cell lineage, meanwhile the self-renewal and 
multipotency is lost. Taken from (Ema, Kobayashi, & Nakauchi, 2010). 
 
Mesenchymal stem cells (MSCs) are another type of adult stem cell that can 
differentiate into a variety of tissues, including adipocytes, chrondrocytes, 
myocytes, fibroblasts, neurons, osteocytes and epithelial cells. The majority of 
MSCs reside primarily in bone marrow, and can be recruited through cell 
signaling molecules to home to certain tissues and differentiate when needed 
(Zhuge, Liu, & Velazquez, 2010). 
Stem cells are known to localize to a specialized microenvironment called a 
‘niche,’ in which they receive extrinsic regulatory signals through cell-cell and 
cell-matrix connections, hormones, and other signaling molecules. These signals 
regulate stem cell behavior, the most crucial component being the decision to 
self-renew or differentiate. If the stem cell leaves its niche, it will differentiate by 
default, indicating the signals involved in the niche help to maintain the stem cell 
state (Ferraro, Celso, & Scadden, 2010).  
Thus, the balance of stem cell supply to differentiated tissue is controlled by a 
host of mechanisms, including cell-cell contact between stem cells and their 
progeny. In contrast to the above example, if a mature, differentiated cell loses 
contact with the stem cell base layer, it can revert to a stem cell, or de-
differentiate. This was demonstrated in recent experiments by Tata et al, where 
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laser ablation of the stem cell basal layer in the airway epithelium caused mature 
surrounding cells to proliferate and some de-differentiated to restore the stem cell 
population. In vitro experiments revealed the mechanism which normally 
prohibited this de-differentiation was cell-cell contact. Moreover, it was shown 
that depending on the degree of maturity, certain cells were more capable of de-
differentiation than others, pointing to a spectrum of transitional changes from 
one phenotype to the other (Tata et al., 2013).  
In response to extrinsic signaling, various intracellular signaling pathways are 
activated. Of particular interest in cancer research are the pathways involved in 
stem cell self-renewal, namely Notch, Wnt, Hedgehog and TGF-b. These 
pathways are illustrated below. 
 
Notch Pathway 
The Notch pathway has been implicated in regulating cell-cell communication – 
as indicated in Figure 16 by the neighboring cell, the Notch-Jagged connection is 
made between two cells of close proximity, and regulates stem cell self-renewal. 
Overexpression of Notch signaling molecules has been noted in certain cancers 
including ovarian, and has been linked to platinum resistance (McAuliffe et al., 
2012). Drugs which target gamma-secretase have been developed (GSIs) and 
have been shown to eliminate cancer stem cell populations and restore 
chemosensitivity (McAuliffe et al., 2012) 
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Figure 16. The Notch Pathway. Upon activation of the Notch receptor by the 
ligand ‘Jagged,’ two proteases are activated – extracellular ADAM proteinase 
and intracellular gamma-secretase. The intracellular fragment of Notch (ICN) falls 
off the receptor as a result and translocates to the nucleus to dislodge a 
corepressor (CoR) and initiate transcription of Notch target genes such as Hes1. 
Taken from (Heidel, Mar, & Armstrong, 2011) 
 
Wnt Pathway 
The Wnt pathway is involved in regulation of stem cell self-renewal, proliferation, 
differentiation, and apoptosis by activation of transcription through its central 
mediator, b-catenin, as shown in Figure 17. In addition, it is thought to be a 
major signaling pathway involved in epithelial-mesenchymal transition (EMT) 
necessary for tumor invasion and metastases (Neth et al., 2007). Dysregulation 
of the Wnt pathway has been strongly associated with several cancers including 
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ovarian, where it has been shown to affect tumorigenesis and progression (Arend 
et al., 2013). 
 
Figure 17. Wnt Signaling Pathway. In the absence of Wnt signaling, the b-
catenin molecule is associated with APC, GSK-3 and axin. In this complex, b-
catenin is phosphorylated by GSK-3 and CK1, and is thus marked for 
proteosomal degradation. Gene transcription does not occur, as the TCF/LEF 
transcription factor is bound and inhibited by Groucho. When Wnt binds to its 
receptor, Frizzled, b-catenin is released from the inhibitory complex and able to 
translocate to the nucleus, dislodge Groucho and initiate gene transcription. 
Taken from (Heidel et al., 2011). 
Hedgehog pathway 
 
 
The Hedgehog pathway is involved in maintaining cell polarity, and the balance 
between stem cell supply and demand through regulation of proliferation and 
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differentiation. Dysregulation of this pathway has been correlated with basal cell 
carcinoma among other cancers, and the FDA approved drug vismodegib has 
been used to treat BCC by antagonizing the receptor Smoothened (SMO), shown 
below in Figure 18. 
 
Figure 18. The Hedgehog Pathway. In the absence of Hh, the transmembrane 
receptor Patched (Ptch) inhibits another receptor, smoothened (Smo). Upon 
binding of Hh to Ptch, it releases the inhibition on Smo, and Gli transcription 
factors are released from Smo to initiate gene transcription. Taken from (Heidel 
et al., 2011). 
 
TGF-β pathway 
TGF-beta signaling is initiated by a large number of different ligands, and makes 
up the TGF-β superfamily (Figure 19). Ligands include the canonical TGF-βs, of 
which there are three, Nodal, and bone morphogenic protein (BMPs). These 
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pathways are critical during embryogenesis as well as in maintaining self-renewal 
and senescence in adult stem cells (Gaarenstroom & Hill, 2014). 
 
Figure 19. TGF-beta superfamily signaling pathways. TGF-b ligands are held 
by latency associated peptides (LAPs) and bound in the extracellular matrix 
(ECM) until they are released by various mechanisms (dashed arrow). TGF-b 
can then bind to a variety of Type I and Type II serine-threonine kinases. 
Subsequent phosphorylation of R-Smads occurs, and there are two major 
divisions which vary based on the ligand/receptor. Inhibitory Smads6 inhibits only 
one branch of the signaling pathway, while Smad7 can inhibit both. 
Phosphorylated Smads join with co-Smad to translocate to nucleus and regulate 
gene transcription. Figure taken from (Oshimori & Fuchs, 2012). 
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Stem Cells and Cancer 
Tumors have been conceptualized as an “aberrant organ” which originates, as in 
normal development, from a multipotent stem cell, capable of differentiating into 
a wide range of  heterogeneous cell types; except in the case of cancer, the 
initiating cell has undergone a cancerous transformation which allows it to 
proliferate in the absence of regulatory controls (Reya, Morrison, Clarke, & 
Weissman, 2001). The classical example of this process is found in 
teratocarcinoma, where multiple differentiated tissues types such as cartilage 
and bone coexist within a single tumor (Figure 20), indicating the involvement of 
a progenitor cell (a human mesenchymal stem cell) which differentiated 
abnormally into various tissue types independent of external queues. Other 
cancers, including breast and ovarian, have also shown heterogeneously 
differentiated cell populations, and these findings fuel questions about the role of 
stem cells in generating tumors (Abelson et al., 2012; Smart et al., 2013). If 
cancer stem cells do exist, and tumorigenic cells can differentiate into the 
remarkably heterogeneous populations comprising a tumor, this could have wide-
reaching implications for new targeted drug therapies. The following section will 
highlight some of the connections found between normal stem cell behavior and 
the nature of tumor progression. 
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Figure 20. Metastatic Teratocarcinoma. Case study of a 26-year-old patient 
with known teratocarcinoma of the testicle was found in autopsy to have cartilage 
deposits in the left anterior descending coronary artery which led to cardiac 
arrest and death of the patient. Cartilage deposits were also found in the lung. 
Both were a result of metastasis of the teratocarcinoma. Taken from (Nath, 
Bhattacharya, & Bharadwaj, 2011). 
 
Stem cells and cancer cells may have similar patterns of division (Figure 21) 
which illustrate a few common traits. A key feature shared between stem cells 
and some cancer cells is self-renewal – a complex and necessary function which 
involves not only the ability to divide asymmetrically, but to balance the supply of 
stem cells with the amount of daughter cells. This process is highly regulated in 
normal stem cells and involves the pathways described in the previous section. 
When these pathways become dysregulated, aberrent self-renewal, proliferation, 
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and independence from external signaling can result in the development of 
cancer. For example, mutations that inappropriately activate the Wnt and 
Hedgehog pathways have been shown to cause colorectal cancer and basal cell 
carcinoma, respectively (Taipale & Beachy, 2001). Dysregulation of neural stem 
cell signaling pathways also leads to cancer; when pathways which regulate self-
renewal are constitutively active it has been shown to cause primary 
glioblastoma multiforme (Zhu & Parada, 2002). Turning off these pathways, in 
converse, tends to reverse cancer progression (Liu, Albrecht, Ni, Yang, & Li, 
2013).These findings suggest the same pathways that regulate self-renewal 
processes in normal stem cells are important in tumorigenesis and cancer 
progression. 
 
Another feature common to stem cells and cancer is differentiation into daughter 
cells with reduced proliferative potential – this hierarchy lies at the core of the 
CSC theory. A number of studies in which isolated subpopulations of cancer cells 
were transplanted into immunodeficient mice found that only a small subset of 
cells were capable of generating tumors, and these tumors recapitulated the 
heterogeneous parental disease, including phenotypes with limited proliferative 
potential (Al-Hajj, Wicha, Benito-Hernandez, Morrison, & Clarke, 2003; Lapidot et 
al., 1994; Singh et al., 2003). Thus, tumor populations consist of a variety of 
phenotypes with differing tumorigenic potential, similar to the stratification in 
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normal tissues, where undifferentiated stem cells co-exist with their differentiated 
daughter cells. 
 
Figure 21. Normal Stem Cell Vs. Cancer Stem Cell. a) Totipotent embryonic 
stem cells develop into different lineages of stem cells that are self-renewing and 
give rise to all tissues in the body. b) If normal stem cells undergo a certain 
number of mutations they can become cancerous while retaining self-renewing 
properties. Alternatively, a mature cell may de-differentiate into a stem cell and 
acquire self-renewing abilities, at the same time, acquiring other mutations that 
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transform the cell into a malignant cancer stem cell. Figure taken from (Pardal et 
al., 2003). 
 
The first example of a “cancer stem cell” was found in human acute myeloid 
leukemia (AML). In 1994, Lapidot et al reported the discovery that a particular 
cell phenotype, CD34+/CD38-, could recapitulate all features of AML disease in 
mice upon transplantation, while CD34+/CD38+ and CD34- fractions could not 
(Lapidot et al., 1994). These and subsequent findings strongly support a 
hierarchical organization whereby a single primitive stem cell gives rise to all 
subpopulations of cells, which possess remarkable heterogeneity (Bonnet & 
Dick, 1997). Other examples where cancer stem cells have been identified 
include breast cancer and glioblastoma, and the work that has spanned over a 
decade has been summarized in reviews (Badve & Nakshatri, 2012; Dontu, Liu, 
& Wicha, 2005; Stopschinski, Beier, & Beier, 2013). In each case, similar to the 
AML model, cancer stem cells are identified based on their ability to initiate 
tumors and recapitulate the heterogeneous disease in vivo upon injection into 
immunocompromised mice. Cell surface markers, namely CD24-/CD44+ in 
breast and CD133+ in glioma cells, were identified as markers of their respective 
cancer stem cells. 
In contrast to AML and other cancers, a study on melanoma revealed that a large 
percentage, between 25-27%, of cancer cells isolated from primary and 
metastatic sites are capable of initiating a tumor in severely 
immunocompromised mice (Quintana et al., 2008). These findings conflicted with 
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previous results in mice with more in-tact immune systems, and brought attention 
to the possibility that xenotransplantation assays may underestimate the 
tumorigeneicty of cancer cells in other studies because of a remnant immune 
response. It also suggested that some cancers such as melanoma may not 
follow the stem cell model, or that they may differ on the extent to which cancer 
stem cells are involved. 
Although the identification and characterization of cancer stem cells in AML, 
breast cancer and glioblastoma have been intensively studied, the existence of 
ovarian cancer stem cells is a matter of heated debate. One aspect that is 
complicating the study of ovarian cancer stem cells is lack of consensus on the 
true cell of origin – fallopian tubal epithelium vs ovarian surface epithelium. Yet 
even in organ systems which have been robustly characterized in terms of stem 
cells and their niche, such as in the intestinal crypt (Barker, 2014), controversy 
ensues on the reliability of cell surface markers in detecting and identifying 
tumorigenic cells. Advanced techniques such as lineage tracing are now allowing 
scientists to study longitudinal stem cell behavior and function in vivo (Blanpain & 
Simons, 2013). Recent findings on new markers such as Lgr5 using this 
technique have been reported, and will need to be confirmed by independent 
groups (Barker, 2014).  
In the following section, current knowledge of ovarian cancer stem cells will be 
discussed. 
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Evidence for Ovarian Cancer Stem Cells 
Identification of a cancer stem cell involves a series of more or less defined 
experiments to test whether the certain stem-like features are present within a 
purified population of cancer cells. The sources of these cell populations can be 
cancer cell lines, tumors generated from mouse models, or preferably, primary 
ovarian cancer samples. In order to be classified as a cancer stem cell, the 
following criteria must be met (Table 5): 
 
Table 5. Qualities of a Cancer Stem Cell. Adapted from ( Shah & Landen, 
2014) 
• Increased tumorigenic capability in xenograft models 
• Clonogenic (ability for form a colony from a single cell) 
• Unlimited self-renewal 
• Pluripotency (ability to produce distinct, differentiated daughter cells) 
• Ability to recapitulate heterogeneous parental disease 
• Chemoresistance 
• Radiation resistance 
• Form spheroids in suspension 
 
The first paper to describe stem-like behavior in ovarian cancer emerged in 2005. 
Bapat and colleagues isolated and propagated ascitic cell spheroids from a 
patient with advanced stage disease, and characterized 10 representative clones 
that had spontaneously immortalized in culture. RT-PCR detected up-regulation 
of vimentin, E-Cadherin (in all but one clone), cytokeratin 18, c-met and EGFR, 
and surface adhesion molecule CD44. Stem cell pathway proteins Snail and Slug 
were present, although the pathway in which they are involved, c-kit-SCF, was 
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expressed differentially among the clones, suggesting they existed at different 
phases in the epithelial to mesenchymal spectrum. Only two of 10 representative 
clones were able to form colonies in soft agar, (clonogenic), and they were found 
to express stem cell mediators, Nestin, Nanog, and Oct4. These clones, when 
injected into nude mice subcutaneously and intraperitoneally both formed tumors 
and metastases, although one was more aggressive than the other, and had a 
more epithelial phenotype which resembled the patient sample. Each of the 
clones were capable of regenerating tumor upon serial implantation to other mice 
(Bapat, Mali, Koppikar, & Kurrey, 2005). This study met some but not all of the 
criteria listed in Table 5, namely the characterization of heterogeneity and 
pluripotency was not addressed, nor was chemoresistance. Regardless, this 
study marked the first evidence for the possibility of ovarian cancer stem cells, 
and a plethora of subsequent investigations followed. 
Potential cancer stem cells are isolated from a heterogeneous population of 
primary tumor cells in various ways – this process is also called “prospective 
identification”. In the above example, Bapat and colleagues had selected clones 
based on behaviors in cell culture, such as clonogenicity in agar and ability to 
form spheroids, or anchorage-independent structures, that are characteristic of 
normal stem cells (Sukach & Ivanov, 2007). Other studies have followed this 
method of selecting clones in ovarian cancer (S. Zhang et al., 2008) and other 
cancers such as breast (Saadin & White, 2013). Another strategy for selecting 
subpopulations is based on cell surface markers that are known to be associated 
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with stem cells, such as CD133. Fluorescence-activated cell sorting (FACS) is 
the method of choice for this selection process, and many cell surface markers 
have been employed in the search for ovarian cancer stem cells (Table 6).  
 
CD133 is of particular interest because of its unique expression in hematopoietic 
and epithelial stem cells, and since it had been used to successfully identify 
tumor initiating cells in brain, pancreatic, liver, skin, prostate and colon cancers 
(Baba et al., 2009). The function of CD133 is largely unknown. Several studies 
have shown that CD133+ ovarian cancer cells, isolated from patient samples as 
well as those originating from ovarian cancer cell lines, have enhanced 
tumorigenecity compared to CD133- cells (Baba et al., 2009; Curley et al., 2009; 
Kusumbe, Mali, & Bapat, 2009). Interestingly, one study showed that CD133+ 
cancer cells have a remarkable ability to induce angiogenesis, suggesting a 
potential role in modifying and creating heterogeneity in the extracellular 
environment (Kusumbe et al., 2009). Despite numerous studies that implicate 
CD133 as a stem cell marker, doubt remains as to the true relevance of CD133 
in identifying a cancer stem cell, as it has been shown that CD133- cells can also 
be tumorigenic, and tumorigenicity of CD133+ cells seems to depend on the 
subtype of cancer and the context in which it is tested (Stewart et al., 2011).  
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Table 6. Ovarian Cancer Stem Cell Markers. Adapted from (M. M. Shah & 
Landen, 2014). 
 
 
Marker   Conclusions       
CD133+ Increased tumorigenesis and angiogenesis, associated 
with poor prognosis (Baba et al., 2009; Curley et al., 2009; 
Kusumbe et al., 2009; Silva et al., 2011; Jing Zhang et al., 
2012) 
CD44+/MyD88+ Increased tumorigenesis and chemoresistance (Alvero et 
al., 2009) 
CD44+/CD117+ Increased tumorigenesis and chemoresistance (S. Zhang 
et al., 2008) 
CD44+/CD24- Spheroid formation, recapitulate parental tumor (cell lines) 
(Shi et al., 2010) 
CD44+/CD24+ Increased tumorigeneis (primary tumor/xenograft) (Gao, 
Choi, Kang, Youn, & Cho, 2010) 
ALDH1A1+ Increased tumorigenesis and pluripotency (Landen et al., 
2010) 
ALDH1A1+/CD133+ Increased tumorigenesis, chemoresistance and self-
renewal (Kryczek et al., 2012; Silva et al., 2011) 
ABCG2 (side pop’n) Increased tumorigenesis, chemoresistance and self-
renewal (Dou et al., 2011; Hu, McArthur, & Jaffe, 2010; 
Kobayashi et al., 2011; Szotek et al., 2008) 
   
Much conflicting evidence has been put forth concerning the implications for cells 
expressing certain markers. Of particular controversy has been the cell marker 
aldehyde dehydrogenase (ALDH), a cytosolic enzyme which has been 
associated with a stem cell behaviors in a number of cancers including breast 
and colon (Huang et al., 2009; Kim et al., 2013). In some cases, ALDH 
expression is associated with poor clinical outcomes (Deng et al., 2010; Landen 
et al., 2010; Silva et al., 2011) while in others it is not (B. Chang et al., 2009; 
Penumatsa, Edassery, Barua, Bradaric, & Luborsky, 2010). An explanation for 
these dichotomous findings is that ovarian cancer is a heterogeneous disease – 
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what may be true in one case may not apply to another. Moreover, Chang et al 
found that ALDH had the highest expression in early-stage endometrial ovarian 
cancer, and correlated with a longer survival, however failed to distinguish 
between various subtypes of carcinoma that have inherently different prognoses.  
Interestingly, one study may explain previous conflicting evidence for the role of 
CD133 as a CSC marker. This group found that tumorigenicity of cells 
expressing CD133 was variable and depended on co-expression with ALDH 
(Landen et al., 2010), suggesting that the CD133+ cells that were found to lack 
tumorigenic capacity in other studies may have been negative for ALDH. These 
findings illustrate the complex problem of prospective identification of cancer 
stem cells, and that one marker is likely insufficient for a confident definition. 
Moreover, even multiple markers that identify cancer stem cells in certain cases 
may not identify them in others, and the CSC phenotype likely depends on the 
cell of origin and unique tumorigenic process that occurred in a particular patient. 
 
A useful perspective into the nature of stem cell markers was obtained in one 
study that used FACS to separate CD24+ and CD24- cells, originally isolated 
from the same primary ovarian cancer tumor, and subsequently compared them 
for expression of stem cells genes (Gao et al., 2010). RT-PCR revealed that 
CD24 expression is accompanied by enrichment of β-catenin, Bmi-1, Notch1 and 
Notch4, and lower levels of E-Cadherin (Figure 22). This result is interesting 
because it suggests a correlation between CD24 and cancer stem cell function, 
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and identifies candidate pathways that might be involved. Moreover, the use of a 
proper control – cells were derived from the same source, cultured in the same 
conditions, and separated based only upon their expression of CD24 or lack 
thereof – removes variability and doubt from the findings. More studies like this, 
which help to correlate programs associated with the surface markers and stem 
cell behaviors are needed – as personalized medicine envisions individual 
patient sample analysis for stem cell markers informing a targeted therapeutic 
approach. Further, understanding these relationships will bring confidence for the 
use of surface markers in identifying ovarian cancer stem cells and put to rest the 
confusion that has arisen from attempts to oversimplify the multifaceted 
characteristics of cancer stem cells by hastily assigning to them a handful of 
surface markers, many of whose functions remain unknown especially in relation 
to stem cell biology.  
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In summary, a multitude of reports have claimed that cancer stem cells are 
“defined” by the presence of certain markers, however there is obviously conflict 
about which are relevant. It seems there are a variety of markers that could be 
potentially used to identify cancer stem cells, depending on the source of the 
original population, suggesting that cancer stem cells themselves are 
heterogeneous. A more accurate statement, therefore, may be to claim that 
cancer stem cells may possess certain surface markers, such as CD133, but 
aren’t necessarily defined by them. Surely, before we can define cancer stem 
Figure 22. RT-PCR reveals 
connection between CD24 
and stem cell function. 
Cells isolated from a primary 
tumor of ovarian cancer were 
purified and separated by 
FACS based on the 
presence of CD24 surface 
marker. CD24 expression 
was accompanied by 
increased levels of b-catenin, 
Bmi-1, Notch1 and Notch4, 
as well as decreased 
expression of E-cadherin. 
Taken from (Gao et al., 
2010). 
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cells based on these markers, we must first understand their functions and how 
they relate to, or regulate, stem cell behavior. In any case, it seems we are just 
beginning to crack the surface on what defines a cancer stem cell, and the 
variety of cell surface markers, pathways and mechanisms that define them. 
In contrast to the work being done in prospective identification of cancer stem 
cells in vitro, clinical data is solidifying the notion that stem-cell like populations 
exist in ovarian cancer. The significance of these populations has been 
investigated in terms of chemoresistance, prognosis, and targeted therapy. A 
robust study by Steg et al examined 45 matched primary/recurrent tumor pairs of 
aggressive high grade serous ovarian carcinoma for the presence of stem cell 
markers and pathways. Specifically, immunohistochemistry and quantitative PCR 
revealed that ALDH1A1, CD44, and CD133, along with genes in the TGF-β, 
Hedgehog, Notch, and Wnt pathways were elevated in specimens collected 
immediately after treatment. Interestingly, upon tumor recurrence (12-18 months 
later), the levels of these markers went back to the original values in the primary 
tumor sample – suggesting the stem-like population which persisted during 
treatment differentiated to recapitulate the original disease heterogeneity within 
this timeframe (Steg et al., 2012). In another study, the extent of cancer stem 
cells (identified by cell surface marker CD44) that were found to be in biopsy 
samples was negatively predictive of progression-free survival in early stage 
ovarian cancer (Steffensen et al., 2011). Furthermore, a targeted therapeutic 
approach aimed at CD44+ used a novel nanoscale siRNA drug delivery system 
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showed this drug was able to irradicate patient-derived malignant tumors in vitro 
and in vivo, providing support that CSCs defined by CD44+ are viable targets for 
therapy (V. Shah et al., 2013).  
Although many questions remain about the nature of cancer stem cells, abundant 
evidence has proven their existence in ovarian cancer, and clinical relevance in 
chemoresistance and as potential targets for future therapies. Further work is 
needed to characterize ovarian cancer stem cells and the variability of cell 
surface markers expressed. 
Validity of the cancer stem cell model in predicting intratumoral 
heterogeneity 
Conceptually, there are various reasons why a stem cell model makes sense in 
explaining the pathogenesis of ovarian cancer. Shah and Landen present several 
ideas: the clinical course itself as evidence – the fact that certain cells respond 
differently to treatment and can survive chemotherapy – suggests that a rare 
resistant population exists that evades traditional targeting of rapidly proliferating 
cells. Further, there is evidence for stem cells in the fallopian epithelium and 
stem-like cells on the ovarian surface epithelium, although there is much to be 
understood about these cells and how they function, it is important evidence that 
stem cell precursors do exist in the tissues speculated to give rise to ovarian 
cancer. In fact, a recent publication revealed a stem cell niche in the ovarian 
surface epithelium that was particularly prone to malignant transformation after 
inactivation of tumor suppressor genes TP53 and Rb1 (Flesken-Nikitin et al., 
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2013). Lastly, the fact that ovarian cancer presents with a wide range of 
phenotypes (serous, clear cells, mucinous, etc) and that these subtypes are often 
found mixed in the same patient, suggests the possibility of a common cell of 
origin – a stem cell with remarkable differentiating capabilities (Shah & Landen, 
2014). 
Validating the cancer stem cell model will require designing more robust 
protocols to identify and study these subpopulations of tumor initiating cells. 
Much criticism has been applied toward the cancer stem cell theory in general 
due to the unreliability of stem cell markers in predicting tumorigenic cell 
populations in large cohorts of different patients and cancer types (Magee, 
Piskounova, & Morrison, 2012; Meacham & Morrison, 2013). In fact, isolation of 
cancer stem cells based on cell surface markers could be a flawed approach to 
capture an elusive population of cells which are as heterogeneous as the disease 
itself, displaying a multitude of cell surface markers, many with unknown 
functions, which vary widely from patient to patient with the same disease and 
therefore aren’t necessarily universal identifiers. Vermeulen et al has taken a 
new approach toward identifying cancer stem cells not by cell surface marker, 
but based on the activity of signaling pathways which are known to be associated 
with stem cell functions (Vermeulen et al., 2010). Finding cancer stem cells 
based on function and behavior, rather than surface markers, avoids putting the 
cart before the horse, which has unfortunately led to much confusion and doubt 
for the cancer stem cell model.  
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Other critics point out the nature of the tumorigenesis assay that involves the 
xenograft transplantation of cancer stem cells into immunocompromised mice. 
They argue this experiment may be misleading due to the foreign 
microenvironment, which may not allow certain cell populations to grow that 
would otherwise be tumorigenic in the host (Magee et al., 2012; Meacham & 
Morrison, 2013). Further evidence of the importance of the microenvironment is 
provided by Abelson et al, which shows that cancer cell populations that wouldn’t 
grow in traditional xenograft models are enabled by providing a human 
embryonic stem cell (hESC)-derived cellular microenvironment. Moreover, the 
function of cancer stem cells is ‘niche-dependent,’ meaning self-renewing 
capacity of cancer stem cells is adaptive and depends on signals from the 
microenvironment; indeed, it is true that xenotransplantation has its limitations in 
studying cancer stem cells (Abelson, Shamai, Berger, Skorecki, & Tzukerman, 
2013). Thus, it is generally agreed that the model for studying cancer stem cells, 
in particular for identifying which cells display tumorigenic potential, could benefit 
from a redesign. 
Genetic/epigenetic variety is often thought of as being too vast to be explained by 
cancer stem cell differentiation alone. The argument is that genetic mutations are 
permanent changes in the genome, while stem cell differentiation is reversible, 
involving epigenetic, plastic changes that alter gene expression (Chen & Dent, 
2014). These reversible changes in genome architecture cannot explain the 
permanent changes in the genome sequence brought about by mutations 
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(Magee et al., 2012). On the other hand, one study used mathematical models to 
simulate cancer progression according to the stem cell theory, and have found if 
cancer did progress according to this theory, increased phenotypical 
heterogeneity would be seen in tumors, vs. a non-CSC model (Sottoriva et al., 
2010). If one were to consider the relatively small number of genetic mutations, 
such as BRCA1/2, consistently found in ovarian cancers, in contrast to the much 
larger number of epigenetic changes involved, it seems likely that the cancer 
stem cell model, which generates heterogeneity through epigenetic changes, 
could be valid in explaining the majority of intratumoral heterogeneity found 
within ovarian cancer.  
The heterogeneous nature of the microenvironment, which includes fibroblasts, 
immune cells and blood and lymph vessels, is known to be regulated by stem cell 
function (Briest et al., 2012). For example, cancer stem cells have been shown to 
induce angiogenesis in several reports (Kusumbe et al., 2009; Li & Zhang, 2013; 
Salnikov et al., 2013). Interactions between cancer stem cells and the 
surrounding stroma have been shown to promote metastatic processes and 
maintain the stem-like state (Malanchi et al., 2012); conversely, cancer 
associated fibroblasts (CAFs) have been shown to increase the “cancer stem cell 
pool” through bone morphogenetic protein 2 (McLean et al., 2011). The 
importance of the stem-cell niche environment has been demonstrated with 
regard to stem cell plasticity as well (Abelson et al., 2013). Whether or not cancer 
stem cells alone are responsible for intratumoral microenvironmental 
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heterogeneity remains a question. Non-stem cell phenotypes are shown to be 
capable of influencing the microenvironment, thus it is likely that a combination of 
both CSC and non-CSC cellular signaling is responsible for the dramatic 
rearrangements seen in the tumor microenvironment, with perhaps CSCs having 
an enhanced ability to orchestrate these changes (Oskarsson, Batlle, & 
Massagué, 2014). 
The ability of cancer stem cells to undergo epithelial to mesenchymal transitions 
(EMTs) is an area of increasing interest in cancer research, as it has been 
implicated in metastatic processes, and is perhaps offers the strongest support 
for the cancer stem cell model. It has been shown in various cancers that 
malignant metastases share features of both EMT and stem cell traits (Thiery, 
Acloque, Huang, & Nieto, 2009). Indeed, many of the same pathways that control 
EMT also regulate stem cell maintenance, self-renewal and differentiation, such 
as Wnt and Notch (Yang & Weinberg, 2008), both of which are found to be 
dysregulated in ovarian cancer (Arend et al., 2013; Cancer Genome Atlas 
Research Network, 2011; Mak et al., 2012). The epigenetic gene silencer, 
‘enhancer of zeste homolog 2’ (EZH2) causes the silencing of E-cadherin 
expression, a critical step in the EMT process (Onder et al., 2008); at the same 
time, EZH2 has been investigated as a stem cell marker in ovarian cancer, as it 
appears to be overexpressed in populations of chemoresistant cancer cells 
(Rizzo et al., 2011). There are numerous examples of the overlapping nature of 
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the cancer stem cell phenotype with EMT programs; the evidence linking these 
two phenotypes is abundant. 
Still, the question ‘which came first’ is a matter of intense and important debate 
(Chang & Mani, 2013). It is possible that normal stem cells undergo a 
transformation to become cancer stem cells, and subsequently undergo EMT to 
metastasize; yet another possibility is that mature, epithelial cancer cells de-
differentiated to a more mesenchymal phenotype, thereby acquiring stem-like 
traits secondarily to initiation of an EMT program. A potential mechanism for the 
latter was proposed – evidence suggests that cancer associated fibroblasts are 
capable of initiating an EMT program in tumor cells through cytokine signaling, 
and that these tumor cells concurrently develop “stemness,” such as 
tumorigenenic capability and self-renewal (Giannoni et al., 2010). This does not 
prove, however, that this is the sequence of events for any or all cancer types; 
the many complex interactions between stem cells and the surrounding stroma 
adds profound uncertainty to this proposed mechanism. Answering the question, 
‘which came first,’ will require a deeper understanding of the cell of origin for 
different cancers through new experimental techniques such as lineage tracing 
(Alcolea & Jones, 2013; Blanpain & Simons, 2013). Until these new techniques 
are mastered and applied to malignant solid tumors, the validity of the cancer 
stem cell model in predicting heterogeneity required for metastasis remains 
plausible but unproven. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
Intratumoral heterogeneity (ITH) has implications for metastases, drug resistance 
and recurrence. A deeper understanding of the nature of ITH will allow for more 
effective treatments. Each source of heterogeneity – genetic, epigenetic, 
microenvironmental, and differentiation/cell plasticity – has proven influential in 
various cancer types. Explaining how this heterogeneity arises in different 
cancers may involve a combination of both clonal evolution and cancer stem cell 
models, but to varying degrees depending on the cancer type. For example, 
melanoma does not fit as well within the CSC model as compared to other 
cancers, and its progression, metastasis, and resistance to treatment may be 
explained best by a model which emphasizes genetic instability and/or 
cooperativity between subpopulations.  
Cell plasticity has been recently suggested to be a critical component of tumor 
progression and metastasis, and the processes that control cell differentiation 
and de-differentiation are prominent in cancer stem cells. Thus, the importance of 
reversible epithelial-mesenchymal phenotypes in cancer stem cells has emerged, 
and shifted the theory from a rigid hierarchical model to a dynamic one, wherein 
differentiated cells can revert back to their stem-like state. This new model will 
permit a wider array of cancer types to be described within its context. 
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Whether or not the evolution of ovarian cancer fits the cancer stem cell model 
remains controversial, however, data suggests that a hierarchy of tumorigenic 
and non-tumorigenic cells does exist in ovarian cancer. A big question is whether 
these tumorigenic cells start out as normal stem cells that undergo cancerous 
transformations, or whether their stem-like properties are gained through genetic 
alterations. Knowing the answer to this question will have important implications 
for treatments that target stem cell phenotypes. In any case, one cannot deny 
that small, rare subpopulations of cancer cells have been found to exhibit 
significantly more potent tumor initiating activity than the majority of tumor cells 
found in ovarian cancer. If cancer stem cells are involved in metastases and 
recurrence, as evidence suggests, it will be important to continue to learn more 
about how to purify and identify these cells for targeted therapy.  
 
Future work in the field of cancer stem cells should include more systematic 
characterization of the various types of cancer stem cells found in ovarian cancer 
patients, as well as development of robust protocols to study their behavior both 
in vitro and in mouse models. Understanding the diversity of CSCs found within 
ovarian cancer will be critical for future personalized medicine approaches that 
employ targeted therapies to eradicate the tumorigenic populations, coupled with 
standard chemotherapy to eliminate the rapidly dividing bulk of tumor. 
Furthermore, exploring the possibility of a stem cell origin for ovarian tumors 
should employ lineage tracing experiments, similar to what has been done for 
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intestinal adenomas (Alcolea & Jones, 2013). Lineage tracing allows for direct 
observation of cell proliferation in vivo using fluorescent reporters that are passed 
down from parent to daughter cell. One group has used this technique to study 
the cancer-prone stem cell niche at the ovarian hilum, (Flesken-Nikitin et al., 
2013), however longitudinal studies that show the nature of progression toward 
metastatic disease are needed to further characterize the stem cell contribution 
during this transformation. 
As we understand more about the causes of intratumoral heterogeneity, we will 
be more informed to design drugs that fight against the advantages, which this 
heterogeneity most certainly lends to the tumor progression. Further exploration 
and characterization of the role of cancer stem cells in establishing intratumoral 
heterogeneity, and how it contributes to tumor progression, is clearly needed. 
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APPENDIX I 
 
The most common subtypes of ovarian cancer are outlined below (information 
taken from (Robert J Kurman & Shih, 2010; McCluggage, 2011; Prat, 2012). 
High Grade Serous Carcinoma (HGSC)  
• Account for 68-71% of ovarian cancers 
• Aggressive phenotype, typically present at advanced stage, with poor prognosis 
• Histological appearance is slightly glandular, with a slit-like lumen, intermediate cell size, 
with occasional giant cells having large nucleoli (Figure 4a). Cells are ciliated columnar 
and produce a clear fluid.  
• The only ovarian subtype with a known risk factor of hereditary BRCA mutations.  
• Commonly express p53, BRCA1, WT1 and p16, and high proliferation is indicated by 
nuclear expression of Ki-67. Also may express estrogen receptor (ER).  
• Cell of origin is a matter of debate as being either from the fallopian tube of ovarian 
surface epithelium.  
• Typically sensitive to first round chemotherapy of platinum/taxane, however recurrent, 
resistant disease will develop and ultimately lead to death of the patient. 
 
Low Grade Serous Carcinoma (LGSC)  
• Uncommon, accounting for <5% of ovarian cancers.  
• Relatively benign phenotype, however should be monitored closely as it can transform 
into HGSC. 
• Forms small papillae with psammoma bodies in the stroma (Figure 4b). Uniformity of 
nuclei is the key distinguishing feature in comparison to HGSC microscopically. 
• Similar expression profiles to HGSC, although Ki-67 is far less, indicating reduced 
proliferation reflective of its generally benign behavior.  
• Although responsiveness to treatment has not been determined, preliminary data suggest 
insensitivity to standard chemotherapeutics. 
 
Mucinous Carcinoma (MC) 
• Accounts for 3-4% of ovarian cancers. 
• Mostly benign (80%) phenotype, however invasion can occur and be difficult to detect. 
• Can resemble gastrointestinal metastases, because the cells are non-ciliated columnar, 
and produce a viscous fluid similar to cells of the GI tract (Figure 4c). Malignant 
mucinous carcinomas are heterogeneous and may contain benign components as well, 
which may confound diagnosis if proper sampling size is not taken. 
• Cells express CDX2 and KRAS which are also found in gastrointestinal cells. Cytokeratin 
7 (CK7) is often expressed and can be used to distinguish from colorectal metastases. In 
contrast to endometriod and serous tumors, MCs are negative for estrogen receptor and 
WT1. 
• Cell of origin is unknown. 
• Response to treatment is largely unknown. Most MCs are benign, and malignant MCs are 
difficult to diagnose due to their heterogeneity. Adding to the rarity of the disease, this 
makes research into its chemosensitivity a formidable challenge.  
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Endometrioid Carcinoma (EC) 
• Accounts for 10% of ovarian cancers. 
• Very benign phenotype and often detected early, therefore having the most favorable 
prognosis of all subtypes.  
• Histologically similar to the appearance of uterine cell lining, and usually EC is associated 
with parallel disease of the endometrium – either carcinoma, cysts, or endometriosis. In 
50% of cases, squamous differentiation can occur (Figure 4d). Although EC can be 
classified as low grade or high grade, most fall into the low grade category, while high 
grade is almost indistinguishable from HGSC.  
• Only subtype with known risk factor of hereditary non-polyposis colon cancer (HNPCC). 
Additional risk factor is atypical endometriosis, especially with PTEN deletion, which is 
also associated with the clear cell subtype. 
• Mutations in AT-rich interactive domain 1A gene (ARID1A) are present in EC, and have 
been found in associated endometriotic tissue. This gene is part of the SWI-SNF-A 
complex that effects transcription, essentially behaving as a tumor suppressor gene via 
its encoded protein, BAF250. This mutation is also present in clear cell carcinoma. Beta-
catenin over-expression is often seen in ovarian EC as a consequence of CTNNB1 gene 
mutations. Mutations in PTEN cause activation of the PI3K-AKT pathway that inhibits 
apoptosis, but this pathway can also be activated through mutations in PIK3CA gene 
which encodes the p110 catalytic subunit of PI3K. ECs express vimentin, cytokeratins, 
epithelial surface antigen, and estrogen and progesterone receptors, but are negative for 
WT1. 
• Cell of origin is proposed to arise from the endometrium or myometrium.  
 
Clear Cell Carcinoma (CCC) 
• Account for 10% of ovarian cancers.  
• Many present at early stages with favorable prognosis, however advanced stage disease 
has the worst prognosis of all ovarian cancer subtypes. 
• Cells have a clear cytoplasm with presence of hobnail phenotype – bulbous protruding 
shape extending from the surface (Figure 4e). Also contain multiple papillae, dense 
basement membrane and hyaline bodies in a quarter of cases.  
• Risk factors include disease of the uterus, similar to endometrioid carcinoma.  
• Unlike HGSCs, CCC is negative for BRCA, ER and WT1, while they are usually positive 
for HNF1-beta, and ARID1A mutations in about half of all cases. Similar to EC, ARID1A 
mutations and absence of BAF250 protein are often found in adjacent endometrotic 
tissue. In particular, overexpression of the transcription factor HNF1-beta in CCC has a 
large impact of pathogenesis because of its regulatory role of several genes including 
dipeptidyl peptidase IV, osteopontin, angiotensin converting enzyme 2, annexin 4 and 
UGT1A1, which are respectively involved in glycogen synthesis, progesterone-regulated 
endometrial secretory protein, ferritin induction/iron deposition/antiapoptosis, paclitaxel 
resistance, and detoxification. It is believed that CCC progression is hindered due to high 
expression of Rho-GDP dissociation inhibitor gamma (ARHGDIG) mRNA, which inhibits 
RHO GTPase pathways involved in cytoskeletal regulation and tumor progression.  
• Cell of origin is proposed to arise from endometrium or myometrium. 
• CCC is typically unresponsive to chemotherapy because of low replication rates and 
relatively stable genetics. 
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APPENDIX II 
Table 4. Regulators of Embryonic Stem Cell Differentiation. Adapted from 
(Heng & Ng, 2010; Yamanaka & Ralston, 2010) ‘ 
 
Regulatory 
Factor  
Role 
Yap/Taz Through phosphylation by Lats1/2 of the Hippo pathway, and 
mechanisms involving cell-cell contact, Yap/Taz localize to nucleus of 
cells destined to become trophoblast lineage, and remain in cytoplasm 
of cells destined to differentiate into inner cell mass. 
Tead4 Binds to Yap/Taz in nucleus to activate DNA transcription of CDX2, 
required for development of trophoblast. 
CDX2 Required for maturation and maintenance of trophoblast, suppresses 
formation of inner cell mass maturation by antagonizing Oct4.  
Oct4 Required for inner cell mass formation, suppresses trophoblast 
formation by antagonizing CDX2. Maintains pluripotency when 
expressed at a neutral level, but if down or up regulated it will induce 
differentiation. Expressed in epiblasts and primordial germ cells in 
addition to inner cell mass. 
Gata 4 and 6 Transcription factors for further differentiation of randomized cells within 
the inner cell mass into the yolk sac, which provides nutrients and 
polarity for the developing fetus. 
Nanog Specifies randomized cells within the inner cell mass which are destined 
to develop into the fetus or yolk sac. Dimerizes and maintains 
pluripotency, but low levels permit differentiation under influence of 
FGF-signaling. Forms complex with Smad1 to inhibit BMP-mediated 
differentiation. Works in parallel to Stat3 by binding members of the NF-
kB pathway and inhibiting differentiation. 
FGF, FGF4 Necessary for yolk sac development. FGF4 required for differentiation 
of epiblast layer. 
Sox2 A pluripotent gene expressed along with Oct4 in epiblast stem cells. 
Maintains pluripotency and self-renewal. Also expressed in neural 
progenitor cells. Forms dimers with Oct4 to regulate a host of embryonic 
stem cell genes. Other homologs (Sox4, Sox11, Sox15) have similar 
capabilities. 
KLF (2, 4, 5) Zinc finger transcription factor that maintains pluripotency and self-
renewal. KLF4 can cause reversion of epiblast cells into their precursor 
stem cells. 
Ronin Transcription factor that interacts with other proteins such as HCF-1 to 
form complexes that mediate pluripotency by suppressing genes for 
differentiation. 
Tbx3, Esrrb Transcription factors involved in preserving self-renewal. 
Sall4, Rif1, 
Dax1, Hdac1, 
Nac1, Zfp281 
Protein partners of Nanog. 
c-Myc, n-Myc, 
Zfx, E2F1 
Cluster of transcription factors that work synergistically with Nanog-
Sox2-Oct4 cluster to effect transcription of genes necessary for self-
renewal and pluripotency. 
P300 Co-activator that binds to enhancer region associated with Nanog-Sox2-
Oct4 cluster and may be involved in DNA looping for faster 
transcription. 
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